{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:04:38Z","timestamp":1773921878351,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1077,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1111\/j.1742-1241.2012.03000.x","type":"journal-article","created":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T01:29:53Z","timestamp":1348104593000},"page":"959-968","source":"Crossref","is-referenced-by-count":9,"title":["Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study"],"prefix":"10.1155","volume":"66","author":[{"given":"F.","family":"G\u00f3mez-Peralta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Carrami\u00f1ana-Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J.","family":"F\u00e9lix-Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fraile-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Extreme Rescue Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,19]]},"reference":[{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB1|cit1","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","volume":"28","author":"Ryden","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","article-title":"Overview of 6\u2003years\u2019 therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","author":"U.K. prospective diabetes study 16","year":"1995","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","article-title":"Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study","volume":"15","author":"Levy","year":"1998","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"10.1111\/j.1742-1241.2012.03000.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes--2011","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2012.03000.x-BIB6|cit6","first-page":"S379","article-title":"Clinical outcomes at 24\u2003months following insulin initiation in Europe: data from the INSTIGATE study","volume":"52","author":"Liebl","year":"2009","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-149-8-200810210-00242","article-title":"Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes","volume":"149","author":"Qayyum","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/diacare.28.2.419","article-title":"Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride","volume":"28","author":"Standl","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","article-title":"Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group","volume":"23","author":"Yki-Jarvinen","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2003-39080","article-title":"A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes","volume":"35","author":"Massi","year":"2003","journal-title":"Horm Metab Res"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","article-title":"Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride","volume":"37","author":"Eliaschewitz","year":"2006","journal-title":"Arch Med Res"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1464-5491.2003.00999.x","article-title":"Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients","volume":"20","author":"HOE 901\/2004 Study Investigators Group","year":"2003","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clin Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2012.03000.x-BIB18|cit18","first-page":"2126-PO","article-title":"RESCUE: Reduction of global cardiovascular risk by means of an integral and updated insulin treatment in DM2","volume":"57","author":"G\u00f3mez-Peralta","year":"2008","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diacare.22.3.530","article-title":"Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur","volume":"22","author":"Bradley","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03320906","article-title":"Validaci\u00f3n del cuestionario \u201cDiabetes treatment satisfaction questionnaire\u201d (DTSQ) en la poblaci\u00f3n espa\u00f1ola","volume":"3","author":"Gomis","year":"2006","journal-title":"Parmacoeconomics - Spanish Research Articles"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-Jarvinen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-1241.2012.03000.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diacare.23.5.644","article-title":"Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo","volume":"23","author":"Heinemann","year":"2000","journal-title":"Diabetes Care"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2012.03000.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2012.03000.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:21Z","timestamp":1643349981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2012.03000.x"}},"subtitle":["Switching premixed insulin to basal plus OADs"],"short-title":[],"issued":{"date-parts":[[2012,9,19]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2012.03000.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,19]]}}}